Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
Before we get into specifics of GNCM, in an exciting series of events aimed at building shareholder value, Pure Hospitality Solution, Inc. (OTCMKTS:PNOW), the creator of Oveedia and the quickly growing Numismatic Specialty Store, Meso Numismatics, announced that the company will award shareholders with a very generous preferred stock...
In the last trading session, the stock price of Novavax, Inc. (NASDAQ:NVAX) gained over 14% to close the session at $1.62 on more than normal volume. No specific news accounts for this move. Last month, it commenced a Phase II clinical study evaluating the immunogenicity and safety of its...
Heat Biologics Inc (NASDAQ:HTBX) recently said that the survival results and top-line response of Phase 1b study evaluating lung cancer treatment with Bristol-Myers Squibb’s drug showed positive signs. The company reported HS-110/Nivolumab Combination for treating non-small cell lung cancer (NSCLC) in Austria at International Association for the Study of...
There are 30.1 million Americans with diabetes, 380 million worldwide means a vast, wide-open market. It’s a public health crisis like few others – 9.4% of Americans have diabetes. And, the drug that keeps them alive – insulin – is made by just three multinational corporations. In fact, 3 pharmaceutical giants...
Aducanumab, a clinical treatment drug, primed to treat those with early symptoms of Alzheimer’s, recently went into Phase 1B clinical studies trial. Recently, the firm responsible for the manufacturing of the clinical treatment drugs, Biogen Inc. (NASDAQ:BIIB) released the data obtained from the Phase 1B trial. The data will be...
Conatus Pharmaceuticals Inc (NASDAQ:CNAT) inked an alliance agreement with Novartis for development of their lead product, a drug called emricasan. The transaction was done with an upfront cost of $50 million and around $650 million to be paid in milestone payments in the times to come. Novartis gets emricasan’s rights...
Array Biopharma Inc (NASDAQ:ARRY) a biopharmaceutical firm focused on the development, commercialization and discovery of targeted small molecule cancer treatments reported financial results for 2Q2017 and released an update on the development of its major clinical development plans. Ron Squarer, the CEO, reported that they are delighted to announce that...
Shares of (NASDAQ:) are currently up by more than from the open today and are trading at $. More than shares have exchanged hands compared to an average trading volume of . At the current pps, the market cap stands at $. The stock prices of...
We are going to take a close look at () today to get a better sense of the company and its current status, as well as the opportunity it may offer for prospective investors. Today's focus will be a fundamental evaluation of the stock from top to bottom. As...